New combo therapy shows promise for tough lung cancer
NCT ID NCT03589547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of an immune-boosting drug (durvalumab) and a precise, high-dose radiation treatment (SBRT) for people with stage III lung cancer that hadn't spread. The goal was to see if adding SBRT after standard chemoradiation could help control the cancer longer. Eleven participants were enrolled to check safety and how well the treatment worked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glowing drug reveals why lung cancer immunotherapy fails
- Gene-Hacked immune cells take on tough cancers
- Thymus gland may hold key to preventing immune cell loss during lung cancer treatment
- Lung cancer radiation study pulled before it even started
- New lung cancer combo aims to boost treatment completion
- Blood test may personalize lung cancer therapy